147 related articles for article (PubMed ID: 8740842)
1. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts.
Washington K; Gottfried MR
Liver; 1996 Apr; 16(2):99-104. PubMed ID: 8740842
[TBL] [Abstract][Full Text] [Related]
2. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
3. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
4. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas.
Teh M; Wee A; Raju GC
Cancer; 1994 Sep; 74(5):1542-5. PubMed ID: 7520348
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.
Chuang SC; Lee KT; Tsai KB; Sheen PC; Nagai E; Mizumoto K; Tanaka M
World J Surg; 2004 Oct; 28(10):995-1000. PubMed ID: 15573254
[TBL] [Abstract][Full Text] [Related]
6. Regulators of apoptosis in cholangiocarcinoma.
Jhala NC; Vickers SM; Argani P; McDonald JM
Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
[TBL] [Abstract][Full Text] [Related]
7. p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases.
Arora DS; Ramsdale J; Lodge JP; Wyatt JI
Histopathology; 1999 Jun; 34(6):497-501. PubMed ID: 10383693
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis.
Batheja N; Suriawinata A; Saxena R; Ionescu G; Schwartz M; Thung SN
Mod Pathol; 2000 Dec; 13(12):1265-8. PubMed ID: 11144921
[TBL] [Abstract][Full Text] [Related]
9. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer.
Ahrendt SA; Rashid A; Chow JT; Eisenberger CF; Pitt HA; Sidransky D
J Hepatobiliary Pancreat Surg; 2000; 7(4):426-31. PubMed ID: 11180865
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma of gallbladder: an immunohistochemical profile and comparison with cholangiocarcinoma.
Hughes NR; Bhathal PS
J Clin Pathol; 2013 Mar; 66(3):212-7. PubMed ID: 23268317
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2007 Jun; 31(6):907-13. PubMed ID: 17527079
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs.
Harada K; Sato Y; Ikeda H; Maylee H; Igarashi S; Okamura A; Masuda S; Nakanuma Y
Virchows Arch; 2012 Mar; 460(3):281-9. PubMed ID: 22358181
[TBL] [Abstract][Full Text] [Related]
13. Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma.
Lee CS
Eur J Surg Oncol; 1997 Jun; 23(3):233-7. PubMed ID: 9236898
[TBL] [Abstract][Full Text] [Related]
14. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis.
Rizzi PM; Ryder SD; Portmann B; Ramage JK; Naoumov NV; Williams R
Gut; 1996 Feb; 38(2):265-8. PubMed ID: 8801209
[TBL] [Abstract][Full Text] [Related]
15. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
Lee CS; Pirdas A
Pathology; 1995 Apr; 27(2):117-20. PubMed ID: 7567135
[TBL] [Abstract][Full Text] [Related]
16. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas.
Terada T; Nakanuma Y
Pathol Int; 1996 Oct; 46(10):764-70. PubMed ID: 8916146
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas.
Karamitopoulou E; Tornillo L; Zlobec I; Cioccari L; Carafa V; Borner M; Schaffner T; Brunner T; Diamantis I; Zimmermann A; Terracciano L
Am J Clin Pathol; 2008 Nov; 130(5):780-6. PubMed ID: 18854271
[TBL] [Abstract][Full Text] [Related]
18. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival.
Diamantis I; Karamitopoulou E; Perentes E; Zimmermann A
Hepatology; 1995 Sep; 22(3):774-9. PubMed ID: 7657282
[TBL] [Abstract][Full Text] [Related]
19. [Gallbladder and bile duct carcinoma. Biology and pathology].
Tannapfel A; Wittekind C
Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
[TBL] [Abstract][Full Text] [Related]
20. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
